VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
about
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
P2860
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
VEGF pathway-targeted therapy ...... randomized controlled trials.
@en
VEGF pathway-targeted therapy ...... randomized controlled trials.
@nl
type
label
VEGF pathway-targeted therapy ...... randomized controlled trials.
@en
VEGF pathway-targeted therapy ...... randomized controlled trials.
@nl
prefLabel
VEGF pathway-targeted therapy ...... randomized controlled trials.
@en
VEGF pathway-targeted therapy ...... randomized controlled trials.
@nl
P2093
P2860
P1476
VEGF pathway-targeted therapy ...... randomized controlled trials.
@en
P2093
Qianyuan Zhuang
Xianguo Chen
Youyuan Li
Zhangqun Ye
Zhiquan Hu
P2860
P2888
P304
P356
10.1007/S11596-011-0680-0
P577
2011-12-16T00:00:00Z